- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - -…
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar MarketSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) --…
New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social…
Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules…
New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing…
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available…
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still…
BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to…
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2…
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage…